[1] Pasławski M, Krzyzanowski K, Złomaniec J, et al. Morphological characteristics of malignant solitary pulmonary nodules[J]. Ann Univ Mariae Curie Sklodowska Med, 2004, 59(1):6-13.
[2] Hu H, Wang Q, Tang H, et al. Multi-slice computed tomography characteristics of solitary pulmonary ground-glass nodules:Differences between malignant and benign[J]. Thorac Cancer, 2016, 7(1):80-87. DOI:10.1111/1759-7714.12280.
[3] Zhang Y, Qiang JW, Ye JD, et al. High resolution CT in differentiating minimally invasive component in early lung adenocarcinoma[J]. Lung Cancer, 2014, 84(3):236-241. DOI:10.1016/j.lungcan. 2014. 02.008.
[4] Snoeckx A, Reyntiens P, Desbuquoit D, et al. Evaluation of the solitary pulmonary nodule:size matters, but do not ignore the power of morphology[J]. Insights Imaging, 2018, 9(1):73-86. DOI:10.1007/s13244-017-0581-2.
[5] Groheux D, Hindié E, Trédaniel J, et al. PET-CT for evaluation of the solitary pulmonary nodule:an update[J]. Rev Mal Respir, 2009, 26(10):1041-1055. DOI:10.1019/20094129.
[6] Li Y, Su M, Li F, et al. The value of 18F-FDG-PET/CT in the differential diagnosis of solitary pulmonary nodules in areas with a high incidence of tuberculosis[J]. Ann Nucl Med, 2011, 25(10):804-811. DOI:10.1007/s12149-011-0530-y.
[7] Jögi A, Vaapil M, Johansson M, et al. Cancer cell differentiation heterogeneity and aggressive behavior in solid tumors[J]. Ups J Med Sci, 2012, 117(2):217-224. DOI:10.3109/03009734.2012.659294.
[8] Asselin MC, O'Connor JP, Boellaard R, et al. Quantifying heterogeneity in human tumours using MRI and PET[J]. Eur J Cancer, 2012, 48(4):447-455. DOI:10.1016/j.ejca.2011.12.025.
[9] Burrell RA, McGranahan N, Bartek J, et al. The causes and consequences of genetic heterogeneity in cancer evolution[J]. Nature, 2013, 501(7467):338-345. DOI:10.1038/nature12625.
[10] 寿毅, 陆建平, 陈涛, 等. PET/CT显像淋巴瘤病灶18F-FDG摄取程度与肿瘤增殖性抗原Ki-67相关性研究[J]. 中国医学计算机成像杂志, 2009, 15(3):278-284. DOI:10.3969/j.issn.1006-5741. 2009.03.018.
Shou Y, Lu JP, Chen T, et al. Study of the correlation between 18F-FDG uptake value of lymphoma lesion and tumor's proliferative antigen Ki-67[J]. Chin Comput Med Imag, 2009, 15(3):278-284.  doi: 10.3969/j.issn.1006-5741.2009.03.018
[11] Khan N, Islam MM, Mahmood S, et al. 18F-fluorodeoxyglucose uptake in tumor[J]. Mymensingh Med J, 2011, 20(2):332-342.
[12] 吴剑, 杨湛. 肿瘤浸润前沿细胞的生物学特性[J]. 医学综述, 2007, 13(13):986-988. DOI:10.3969/j.issn.1006-2084.2007.13.012.
Wu J, Yang Z. Bionomics of advancing front cell in tumor invasion[J]. Med Recapit, 2007, 13(13):986-988.  doi: 10.3969/j.issn.1006-2084.2007.13.012
[13] Eberhard A, Kahlert S, Goede V, et al. Heterogeneity of angiogenesis and blood vessel maturation in human tumors:implications for antiangiogenic tumor therapies[J]. Cancer Res, 2000, 60(5):1388-1393.
[14] Dvorak HF. Tumor Stroma, Tumor Blood Vessels, and Antiangiogenesis Therapy[J]. Cancer J, 2015, 21(4):237-243. DOI:10.1097/PPO.0000000000000124.